Orexigen appoints Tom Cannell as chief commercial officer

30 March 2015

US pharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that Tom Cannell has joined as chief commercial officer.

He will take over from Mark Booth, and joins the company after 27 years at Merck & Co (NYSE: MRK), where he held a variety of senior leadership roles such as president of Merck Canada. He has experience in global commercialization, consumer marketing and sales operations.

Mike Narachi, chief executive of Orexigen, said: "We are thrilled to welcome Tom to Orexigen. The strong launch of Contrave (naltrexone HCl/bupropion HCl) in the United States and the recent approval of Mysimba (naltrexone HCl/bupropion HCl) in Europe provide Orexigen with valuable strategic options. We will benefit from Tom's international commercial experience and strong leadership qualifications as we advance our global partnering discussions and evaluate the opportunity to retain or exercise strategic commercial rights for Contrave or Mysimba."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >